The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
BeiGene partners with China’s CSPC for SYH2039
Dec 13, 2024•over 1 year ago
Contract Type
partnership
Biotechnology
Description
BeiGene has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors.
Company Information
Company
BeiGene and CSPC Zhongqi Pharmaceutical Technology
About
BeiGene is a Sino-American biotech company listed on Nasdaq, and CSPC Zhongqi Pharmaceutical Technology is a Chinese company listed on the Hong Kong Stock Exchange.
Predictive Intelligence
Strategic
ML-powered predictions for BeiGene and CSPC Zhongqi Pharmaceutical Technology's next move
